Karen Rudo, MD
Ophthalmology · Milford, DENPI 1982921110
Payments from drug & device makers
What this record shows
Alcon accounts for 63.1% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $1,996, more than ten times the $116 reported in 2019.
Across 53 payments — averaging $90.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Lumenis BE Inc$550
- Oyster Point Pharma, Inc.$318
- Bausch & Lomb Americas Inc.$310
- Coopervision Inc.$126
- Tarsus Pharmaceuticals, Inc.$126
- plus $348 from 7 others
Across 26 payments — averaging $33.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Notal Vision, Inc.$870
What the payments were for
- Travel & lodging$2,20646%
- Food & beverage$2,61254%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 13 | $3,040 |
| Lumenis BE Inc | 1 | $550 |
| Oyster Point Pharma, Inc. | 14 | $318 |
| Bausch & Lomb Americas Inc. | 9 | $310 |
| Coopervision Inc. | 3 | $126 |
| Tarsus Pharmaceuticals, Inc. | 5 | $126 |
| Medtronic | 1 | $100 |
| Aerie Pharmaceuticals, Inc. | 1 | $96 |
| Rxsight Inc | 2 | $61 |
| AbbVie | 1 | $30 |
| Dompe US, Inc. | 1 | $29 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Omeros Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIR OPTIX$1,226
- Dailies Aqua Comfort Plus$704
- optilight$550
- DAILIES TOTAL1 Multifocal$271
- DAILIES TOTAL1$193
- Precision 1$193
- TOTAL30$193
- MIEBO$125
- XIIDRA$125
How this compares
$4,818 in reported general payments places this provider in the 85th percentile of 49 ophthalmology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TyrvayaVarenicline Tartrate | 32 | $51,847 |
| XdemvyLotilaner | 22 | $42,440 |
| RestasisCyclosporine | 13 | $21,852 |
| Latanoprost | 142 | $2,914 |
| Brimonidine Tartrate | 16 | $2,669 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 53 | $1,443 |
| Prednisolone Acetate | 25 | $1,394 |
| Doxycycline Hyclate | 28 | $847 |
| ValacyclovirValacyclovir Hcl | 12 | $738 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 59 | $607 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 11 | $523 |
| ErythromycinErythromycin Base | 27 | $453 |
| MoxifloxacinMoxifloxacin Hcl | 17 | $443 |
| Timolol Maleate | 20 | $344 |
| Diclofenac Sodium | 15 | $174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Oyster Point Pharma, Inc.Tyrvaya | $318 | $51,84732 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $126 | $42,44022 claims |
| AbbVieRestasis | $30 | $21,85213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 49 ophthalmology providers in Delaware.
Other ophthalmology in Milford
- David CreechDover$22K
- Bryan SeiffDover$9K
- Jeffrey MinkovitzWilmington$7K
- Heather DealyWilmington$6K
- Stewart SmithWilmington$6K
- David LuDover$5K
- Richard SherryWilmington$5K
- Scott FudembergRehoboth Beach$5K
- Michael BrosmanWilmington$5K
- Timothy DoyleDover$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.